BENGALURU : Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd said on Monday, even as experts remain divided over its effectiveness.Remdesivir was developed by U.S.
drugmaker Gilead Sciences Inc , which cut its 2020 revenue forecast last month, citing lower-than-expected demand and difficulty in predicting sales of the treatment.
Cipla is among several firms licensed to make and sell generic versions in developing nations. Cipla's version, Cipremi, was commercially launched in July and costs just above $50 per 100 mg vial."From October onwards, (the company is) seeing very sharp increase in (remdesivir) monthly volumes ...